49 filings
8-K
NKGN
NKGen Biotech Inc
29 Apr 24
Entry into a Material Definitive Agreement
4:01pm
8-K
NKGN
NKGen Biotech Inc
24 Apr 24
Entry into a Material Definitive Agreement
7:51pm
8-K
NKGN
NKGen Biotech Inc
11 Apr 24
NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs
8:05am
8-K
NKGN
NKGen Biotech Inc
5 Apr 24
Entry into a Material Definitive Agreement
4:01pm
8-K
NKGN
NKGen Biotech Inc
27 Mar 24
Entry into a Material Definitive Agreement
4:55pm
8-K
mtuzvu77b07hy85n
20 Mar 24
Other Events
4:01pm
8-K
mfiwp43v4bwos5b4nm3d
15 Mar 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:02pm
8-K
xse7vpo5i6l41i
22 Feb 24
Entry into a Material Definitive Agreement
4:01pm
8-K
55s38 16a46
16 Feb 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6:00pm
8-K
wjaugdpd
12 Feb 24
Entry into a Material Definitive Agreement
9:25am
8-K
fn2y0r
8 Feb 24
Departure of Directors or Certain Officers
5:07pm
8-K
9kpa9mnxb1p1zd5r9rfj
22 Jan 24
Entry into a Material Definitive Agreement
6:12am
8-K
cd2d36r7q9
11 Jan 24
Entry into a Material Definitive Agreement
7:50pm
8-K
ompqmwal
8 Jan 24
Entry into a Material Definitive Agreement
5:19pm
8-K
qpt9evzvnrza pajg
28 Dec 23
Other Events
4:14pm
8-K
6to 12srpe1tll6
27 Dec 23
NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease
4:02pm
8-K
pyzy1lylqhxjyb
27 Dec 23
Entry into a Material Definitive Agreement
4:01pm
8-K
r2yvli n940p2
14 Nov 23
NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
4:36pm
8-K
qr8 dd27l7d3hpgdu4l
30 Oct 23
Regulation FD Disclosure
8:05am
8-K
ow5a8 qd6l7an5gme8u
24 Oct 23
Other Events
8:05am